CNBC-TV18's Ekta Batra reports the combo beat high-dose tirzepatide alone at 14.8%, but 27% of patients dropped out over side effects. Lilly plans Phase 3 by end of 2026.
Recap by typeshit. Full story at LinkedIn.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Polskie Radio covers the FDA clearing Lilly's Zepbound to treat obstructive sleep apnea, an earlier approval beyond weight loss.
Huberman says his REM sleep doubled, but Men's Health notes the evidence is mostly rat and small studies, with no safety research on pinealon injections.
Loading…